These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 26873923)

  • 1. Targeting BRCA1- and BRCA2-deficient cells with RAD52 small molecule inhibitors.
    Huang F; Goyal N; Sullivan K; Hanamshet K; Patel M; Mazina OM; Wang CX; An WF; Spoonamore J; Metkar S; Emmitte KA; Cocklin S; Skorski T; Mazin AV
    Nucleic Acids Res; 2016 May; 44(9):4189-99. PubMed ID: 26873923
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Small-Molecule Disruption of RAD52 Rings as a Mechanism for Precision Medicine in BRCA-Deficient Cancers.
    Chandramouly G; McDevitt S; Sullivan K; Kent T; Luz A; Glickman JF; Andrake M; Skorski T; Pomerantz RT
    Chem Biol; 2015 Nov; 22(11):1491-1504. PubMed ID: 26548611
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pan-cancer analysis of co-occurring mutations in RAD52 and the BRCA1-BRCA2-PALB2 axis in human cancers.
    Hamid AB; Frank LE; Bouley RA; Petreaca RC
    PLoS One; 2022; 17(9):e0273736. PubMed ID: 36107942
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selective killing of homologous recombination-deficient cancer cell lines by inhibitors of the RPA:RAD52 protein-protein interaction.
    Al-Mugotir M; Lovelace JJ; George J; Bessho M; Pal D; Struble L; Kolar C; Rana S; Natarajan A; Bessho T; Borgstahl GEO
    PLoS One; 2021; 16(3):e0248941. PubMed ID: 33784323
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic exploitation of tumor cell defects in homologous recombination.
    Powell SN; Kachnic LA
    Anticancer Agents Med Chem; 2008 May; 8(4):448-60. PubMed ID: 18473729
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Small-molecule inhibitors identify the RAD52-ssDNA interaction as critical for recovery from replication stress and for survival of BRCA2 deficient cells.
    Hengel SR; Malacaria E; Folly da Silva Constantino L; Bain FE; Diaz A; Koch BG; Yu L; Wu M; Pichierri P; Spies MA; Spies M
    Elife; 2016 Jul; 5():. PubMed ID: 27434671
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Personalized synthetic lethality induced by targeting RAD52 in leukemias identified by gene mutation and expression profile.
    Cramer-Morales K; Nieborowska-Skorska M; Scheibner K; Padget M; Irvine DA; Sliwinski T; Haas K; Lee J; Geng H; Roy D; Slupianek A; Rassool FV; Wasik MA; Childers W; Copland M; Müschen M; Civin CI; Skorski T
    Blood; 2013 Aug; 122(7):1293-304. PubMed ID: 23836560
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The RAD52 S346X variant reduces risk of developing breast cancer in carriers of pathogenic germline BRCA2 mutations.
    Adamson AW; Ding YC; Mendez-Dorantes C; Bailis AM; Stark JM; Neuhausen SL
    Mol Oncol; 2020 Jun; 14(6):1124-1133. PubMed ID: 32175645
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting HR Repair as a Synthetic Lethal Approach to Increase DNA Damage Sensitivity by a RAD52 Inhibitor in BRCA2-Deficient Cancer Cells.
    Tseng WC; Chen CY; Chern CY; Wang CA; Lee WC; Chi YC; Cheng SF; Kuo YT; Chiu YC; Tseng ST; Lin PY; Liou SJ; Li YC; Chen CC
    Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33922657
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RAD52 inactivation is synthetically lethal with deficiencies in BRCA1 and PALB2 in addition to BRCA2 through RAD51-mediated homologous recombination.
    Lok BH; Carley AC; Tchang B; Powell SN
    Oncogene; 2013 Jul; 32(30):3552-8. PubMed ID: 22964643
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The function of RAD52 N-terminal domain is essential for viability of BRCA-deficient cells.
    Hanamshet K; Mazin AV
    Nucleic Acids Res; 2020 Dec; 48(22):12778-12791. PubMed ID: 33275133
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular pathways: understanding the role of Rad52 in homologous recombination for therapeutic advancement.
    Lok BH; Powell SN
    Clin Cancer Res; 2012 Dec; 18(23):6400-6. PubMed ID: 23071261
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RAD52 aptamer regulates DNA damage repair and STAT3 in BRCA1/BRCA2‑deficient human acute myeloid leukemia.
    Xu Y; Lin Y; Luo Y; Yang Y; Long B; Fang Z; Liu L; Zhang J; Zhang X
    Oncol Rep; 2020 Oct; 44(4):1455-1466. PubMed ID: 32945515
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Simultaneous Targeting of PARP1 and RAD52 Triggers Dual Synthetic Lethality in BRCA-Deficient Tumor Cells.
    Sullivan-Reed K; Bolton-Gillespie E; Dasgupta Y; Langer S; Siciliano M; Nieborowska-Skorska M; Hanamshet K; Belyaeva EA; Bernhardy AJ; Lee J; Moore M; Zhao H; Valent P; Matlawska-Wasowska K; Müschen M; Bhatia S; Bhatia R; Johnson N; Wasik MA; Mazin AV; Skorski T
    Cell Rep; 2018 Jun; 23(11):3127-3136. PubMed ID: 29898385
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The endonuclease EEPD1 mediates synthetic lethality in RAD52-depleted BRCA1 mutant breast cancer cells.
    Hromas R; Kim HS; Sidhu G; Williamson E; Jaiswal A; Totterdale TA; Nole J; Lee SH; Nickoloff JA; Kong KY
    Breast Cancer Res; 2017 Nov; 19(1):122. PubMed ID: 29145865
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Spatiotemporal dynamics of homologous recombination repair at single collapsed replication forks.
    Whelan DR; Lee WTC; Yin Y; Ofri DM; Bermudez-Hernandez K; Keegan S; Fenyo D; Rothenberg E
    Nat Commun; 2018 Sep; 9(1):3882. PubMed ID: 30250272
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Distinct roles of RAD52 and POLQ in chromosomal break repair and replication stress response.
    Kelso AA; Lopezcolorado FW; Bhargava R; Stark JM
    PLoS Genet; 2019 Aug; 15(8):e1008319. PubMed ID: 31381562
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A moving target for drug discovery: Structure activity relationship and many genome (de)stabilizing functions of the RAD52 protein.
    Bhat DS; Spies MA; Spies M
    DNA Repair (Amst); 2022 Dec; 120():103421. PubMed ID: 36327799
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of small molecule inhibitors of RAD52 for breast cancer therapy: in silico approach.
    Kumar M; Dubey R; Kumar Shukla P; Dayal D; Kumar Chaubey K; Tsai LW; Kumar S
    J Biomol Struct Dyn; 2024 Jun; 42(9):4605-4618. PubMed ID: 37288783
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of a Small Molecule Inhibitor of RAD52 by Structure-Based Selection.
    Sullivan K; Cramer-Morales K; McElroy DL; Ostrov DA; Haas K; Childers W; Hromas R; Skorski T
    PLoS One; 2016; 11(1):e0147230. PubMed ID: 26784987
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.